Dk. Sommers et al., LACK OF EFFECT OF AMITRIPTYLINE ON RISPERIDONE PHARMACOKINETICS IN SCHIZOPHRENIC-PATIENTS, International clinical psychopharmacology, 12(3), 1997, pp. 141-145
The interaction between plasma concentrations of the tricyclic antidep
ressant amitriptyline and the metabolism of the new antipsychotic risp
eridone was studied in 12 patients with chronic schizophrenia. Each pa
tient received 3 mg risperidone twice a day for 28 days. Amitriptyline
was coadministered at doses of 50 mg/day on day 15 and 100 mg/day on
days 16 to 21. Amitriptyline did not significantly affect the mean pla
sma concentrations or pharmacokinetics of risperidone in schizophrenic
patients or influence the antipsychotic fraction (the total concentra
tion of risperidone and 9-hydroxyrisperidone, its primary and biologic
ally active metabolite). These results suggest that risperidone dose n
eed not be adjusted when coadministered with amitriptyline at doses up
to 100 mg/day in schizophrenic patients.